Roche Holding traded at 332.40 this Monday March 9th, decreasing 8.80 or 2.58 percent since the previous trading session. Looking back, over the last four weeks, Roche Holding lost 5.33 percent. Over the last 12 months, its price rose by 8.13 percent. Looking ahead, we forecast Roche Holding to be priced at 332.64 by the end of this quarter and at 308.21 in one year, according to Trading Economics global macro models projections and analysts expectations.
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.